Season 5 of Surfing The MASH Tsunami

S5-03.1 - Why Create a New MASLD Nomenclature?

S5-03.1 – Why Create a New MASLD Nomenclature?

In this discussion, Maru Rinella, who co-led the new MASLD nomenclature process, and Jeff Lazarus, who oversaw a large Delphi process that led to the final result, describe how the process came to be.

S5-03 - The New MASLD Nomenclature and How We Got Here

S5-03 – The New MASLD Nomenclature and How We Got Here

Maru Rinella, Jeff Lazarus and Meena Bansal, all key players in the new MASLD nomenclature process join patient advocate Mike Betel, Louise Campbell and Roger Green to discuss the process, the benefits of the outcome, and where things go from here.

S5 - E02 - MASLD Patient Advocates Plan MASH Activities For 2024

S5 – E02: MASLD Patient Advocates Plan MASH Activities For 2024

Leading MASLD patient advocates Tony Villiotti of NASH kNOWledge, Wayne Eskridge of the Fatty Liver Foundation, Jeff McIntyre of the Global Liver Institute, and Milan Mishkevikj of the European Liver Patients Association join Louise Campbell and Roger Green to share their vision of changes in the MASH world in 2024 along with each organization’s hopes, concerns and plans. The discussion covers the advocates’ hopes and concerns for the year as well as the programs and efforts each considers top priority.

S5 - E01.6 - SurfingMASH Is Back! How Can Consumer Behavior Confound MASH Care?

S5 – E01.6 – SurfingMASH Is Back! How Can Consumer Behavior Confound MASH Care?

After a month off in January, SurfingMASH returns for the 2024 calendar year. In this last segment of Episode 1, the co-hosts explore the complexities surrounding advertising and accessibility of metabolic agents in the US market, with a particular focus on how these factors might influence public engagement and healthcare provider education.

S5 - E01 - How might approval of a MASH drug affect patient treatment?

S5 – E01 – How might approval of a MASH drug affect patient treatment?

The first episode of Season 5 of Surfing the MASH Tsunami starts with a brief discussion of what the co-hosts have worked on for the last two months and proceeds to consider the impact on patient treatment of having a MASH drug approved in the US market, particularly in today’s direct-to-consumer weight loss advertising.

Subscribe for free. New podcasts Wednesday Evening / Thursday Morning.

Apple
Spotify
Google
Stitcher
Buzzsprout
YouTube
SoundCloud